Stay updated with breaking news from Biomarker Classes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Elizabeth O’Donnell, MD, and Tomasz Beer, MD, FACP, recap key takeaways from the panel and consider the potential of MCED testing in transforming cancer screening and addressing gaps in early detection.
Key opinion leaders review the rationale behind multi-biomarker approaches and how they're shaping the future of cancer detection and research.
The potential of MCED testing to reduce health inequities and an examination of accessibility, including FDA approval, physician education, patient awareness, affordability, and logistical support.